

SDrug assessment at a glance: A25-144¹

Diflunisal (adults with hereditary transthyretin amyloidosis with stage 1 or stage 2 polyneuropathy)

20 July 2026

¹ This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A25-144. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Adults with hereditary transthyretin amyloidosis (hATTR amyloidosis) with stage 1 or stage 2 polyneuropathy
Intervention	diflunisal
Comparator	vutrisiran
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects	Informative value of the effects
Mortality	∅	–
Morbidity	∅	–
Symptoms	∅	–
Health-related quality of life	∅	–
Side effects	∅	–
	<div>∅</div> <div>↔</div> <div>↑ / ↓</div> <div>↑↑ / ↓↓</div> <div>↑↑↑ / ↓↓↓</div>	<div>No (suitable) data</div> <div>No advantage or disadvantage</div> <div>Small advantage/disadvantage</div> <div>Moderate advantage/disadvantage</div> <div>Large advantage/disadvantage</div>
		<div>–</div> <div>★</div> <div>★★</div> <div>★★★</div>
		<div>Not applicable</div> <div>Low</div> <div>Moderate</div> <div>High</div>

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No suitable data were available.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Diflunisal (hereditäre Transthyretin-Amyloidose mit Polyneuropathie); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 17.04.2026]. URL: <https://doi.org/10.60584/A25-144>.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Diflunisal (Hereditäre Transthyrethin-Amyloidose mit Polyneuropathie (Stadium 1 oder 2)) [online]. 2026 [Accessed: 17.04.2026]. URL: [Nutzenbewertungsverfahren zum Wirkstoff Diflunisal \(Hereditäre Transthyretin-Amyloidose mit Polyneuropathie \(Stadium 1 oder 2\)\) - Gemeinsamer Bundesausschuss](#).

English translations for this project are published at <https://www.iqwig.de/en/projects/a25-144.html>.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237

50679 Köln

Germany

Phone: +49 221 35685-0

Fax: +49 221 35685-1

Email: info@iqwig.de

Internet: www.iqwig.de